Evaluation of safety of percutaneous radiofrequency ablation therapy for metastatic or primary lung cancer

Evaluation of safety of percutaneous radiofrequency ablation therapy for metastatic or primary lung cancer - Evaluation of safety of percutaneous radiofrequency ablation therapy for metastatic or primary lung cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005957

Enrollment

Registered

2011-07-15

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary or metastatic lung cancer

Interventions

Primary or metastatic lung cancer treated by radiofrequency ablation therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Primary or metastatic lung cancer Cases without distant metastasis except for lung Cases whose standard treatment is ineffective or unamenable

Exclusion criteria

Exclusion criteria: Lesion adjacent to large vessels Cases with active infection Cases with active asthma Cases undergone unilateral pneumonectomy Cases whose performance status is over grade 3 Blood cell count: WBC<2,000/ul, granulocyte<1,000/ul Platelet<5x104/ul or PT-INR>1.5 Forced expiratory volume<1L Cases deemed to be inadequate for this treatment

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Time to Progression Overall Survival Objective Response Rate Tumor-marker assessment	—

Countries

Japan

Contacts

Public ContactShuichi Tanoue

Oita University Faculty of Medicine Department of Radiology

stanoue@oita-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026